JLE

Hématologie

MENU

Un nouveau sous-type à haut risque de B-ALL défini par l’expression ectopique de CDX2 et la fusion UBTF::ATXN7L3 Volume 28, numéro 4, Juillet-Août 2022

Illustrations


  • Figure 1

Tableaux

Auteurs
1 Service d’hématologie biologique, hôpital Saint-Louis, AP-HP
2 UMR 7212, Inserm U944, équipe Génome et Cancer, Université Paris Cité
Tirés à part : E. Clappier
Links of interest: Author has no link of interest in relation with this article.

  B-cell acute lymphoblastic leukemias (B-ALL) in adult represent a rare and difficult-to-treat hematological malignancy. B-ALL are characterized by recurrent chromosomal alterations that drive specific oncogenic pathways associated with distinct biological and clinical features, response to treatment and finally, prognosis. Beside the dramatic impact of targeted therapy for BCR::ABL1/Philadelphia (Ph)-positive B-ALL, recognizing other relevant alterations in Ph-negative B-ALL can allow to [...]